Zacks Small-Cap Research
Sponsored – Impartial - Comprehensive

August 7, 2025
David Bautz, PhD
(312) 265-9471
dbautz@zacks.com

scr.zacks.com
101 N. Wacker Drive, Chicago, IL 60606

Imunon, Inc.

(IMNN-NASDAQ)

IMNN: First Patient Dosed in Phase 3 OVATION 3 Trial…

Based on our probability adjusted DCF model that takes into account potential future revenues of IMNN-001 and the PLACCINE technology, IMNN is valued at $45/share. This model is highly dependent upon continued clinical success of the development candidates and will be adjusted accordingly based on future clinical results.

Current Price (08/07/25)	$8.22
Valuation	**$45.00**

OUTLOOK

On August 5, 2025, Imunon, Inc. (IMNN) announced financial results for the second quarter of 2025 and provided a business update. The company recently announced the first patient was dosed in the Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. Three trial sites have been activated thus far, with additional sites, including many from the prior OVATION studies, in the process of being activated. The company has a goal of activating 20 sites by the end of 2025. The OVATION 3 trial includes two interim analyses and is powered at 95% for overall survival improvement, the primary endpoint, in the intent-to-treat population and 99% in the HRD-positive subgroup. To help bolster its balance sheet, Imunon raised more than $3 million following the end of the second quarter of 2025 through warrant exercises and ATM sales. In addition, the company has streamlined operations to help conserve cash, including reductions in G&A expenses and non-core activities.

SUMMARY DATA

52-Week High	**$37.63**
52-Week Low	**$5.99**
One-Year Return (%)	**-48.79**
Beta	**2.16**
Average Daily Volume (sh)	**438,251**
Shares Outstanding (mil)	**2**
Market Capitalization ($mil)	**$17**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**4**
Insider Ownership (%)	**6**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2025 Estimate	**-0.7**
P/E using 2026 Estimate	**-0.7**

Risk Level	**High**
Type of Stock	**Small-Growth**
Industry	**Med-Biomed/Gene**

ZACKS ESTIMATES

Revenue
(In millions of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2024	0.0 A	0.0 A	0.0 A	0.0 A	0.0 A
2025	0.0 A	0.0 A	0.0 E	0.0 E	0.0 E
2026					0.0 E
2027					0.0 E

Earnings per Share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2024	-$7.87 A	-$7.64 A	-$5.03 A	-$4.76 A	-$24.27 A
2025	-$4.23 A	-$2.15 A	-$1.77 E	-$0.93 E	-$6.31 E
2026					-$2.75 E
2027					-$2.40 E

© Copyright 2025, Zacks Investment Research. All Rights Reserved.

WHAT'S NEW

Business Update

First Patient Dosed in Phase 3 OVATION 3 Trial

On July 30, 2025, Imunon, Inc. (IMNN) announced that the first patient has been dosed in the Phase 3 OVATION 3 trial of IMNN-001 for the treatment of women with newly diagnosed advanced ovarian cancer.

The OVATION 3 trial will enroll patients with either Stage IIIc or IV advanced ovarian cancer who will be randomized to receive neoadjuvant chemotherapy (NACT), interval debulking surgery, and adjuvant chemotherapy with or without IMNN-001. The first cohort of patients will focus on those who are positive for homologous recombination deficiency (HDR) and will also be administered poly ADP-ribose polymerase (PARP) inhibitor therapy as part of standard-of-care (SOC) maintenance therapy. The primary endpoint is overall survival (OS), with secondary endpoints evaluating surgical response score, chemotherapy response score, clinical response (ORR), and time to second-line treatment. The following slide provides an overview of the statistical plan for the trial. Final analysis of the trial will occur after 135 events have occurred, however two interim analyses are planned following 68 and 101 events, representing 50% and 75% of the planned final event total, respectively.



Source: Imunon, Inc.

The study was designed to maximize operational flexibility as it is powered at >95% to examine either a 250-patient cohort of HRD positive individuals or a 500-patient all-comers population. The company has decided to initially focus on the HRD positive subgroup as it potentially offers cost savings of up to 40% and could lead to a data readout up to two years earlier. HRD positive patients constitute approximately 50% of the advanced ovarian cancer population, thus it is still a sizeable market opportunity. The company is still committed to examining IMNN-001 in a broader population of patients, however that may need to come at a later time when sufficient financing is available to conduct that study. The decision to target the HRD positive subgroup will help to conserve cash, targeting the highest probability subgroup, and delivering results as quickly as possible. In summary, this design allows Imunon to decrease the initial investment required, decrease the timeline to data readout, and allows the company to be more aggressive with site engagement.



Source: Imunon, Inc.

Phase 2 OVATION 2 Data Presented at ASCO

During the second quarter of 2025, results from the Phase 2 OVATION 2 trial were presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting and simultaneously published in the peer-reviewed journal *Gynecologic Oncology*. The data showed the following:

- Patients in the intent-to-treat (ITT) population that received IMNN-001 plus standard-of-care (SoC) neoadjuvant/adjuvant chemotherapy (N/ACT) had a median increase in overall survival (OS) of 13 months compared to patients who received only SoC N/ACT alone (46 vs. 33 months, HR=0.69).

- For patients also receiving treatment with poly ADP-ribose polymerase (PARP) inhibitors, the mean OS has not yet been reached in the IMNN-001 arm after more than five years compared to 37 months in the control arm (HR=0.38).

- For women who were positive for homologous recombination deficiency (HRD+), including BRCA1 and BRCA2 mutations, the HR was 0.42.

- In addition to an increase in OS, for the ITT population patients treated with IMNN-001 along with SoC N/ACT showed a median 3-month increase in progression-free survival (PFS) compared to SoC N/ACT alone (14.9 months vs. 11.9 months, HR=0.79).

- For patients also receiving PARP inhibitors, there was an 11.7-month increase in PFS for those treated with IMNN-001 and SoC N/ACT compared to SoC N/ACT alone (33.8 months vs. 22.1 months, HR=0.8).

- IMNN-001 was well tolerated, with the most common adverse events (AEs) including abdominal pain, nausea, and vomiting. Importantly, there were no reports of cytokine release syndrome, systemic toxicity, or serious immune-related AEs.

If these results are replicated in the Phase 3 OVATION 3 trial, it may result in transforming the standard of care for advanced ovarian cancer patients, where no improvement in OS has been reported in more than 25 years.

Financial Update

On August 5, 2025, Imunon announced financial results for the second quarter of 2025. As expected, the company did not report any revenue during the second quarter of 2025. R&D expenses in the second quarter of 2025 were $1.2 million compared to $2.8 million in the second quarter of 2024. The decrease was primarily due to lower costs associated with the OVATION 2 study, the Phase 1 PlaCCine DNA vaccine trial, and the development of the PlaCCine DNA vaccine technology. G&A expenses in the second quarter of 2025 were $1.5 million compared to $2.2 million for the first quarter of 2024. The decrease was primarily due to lower employee-related and legal expenses.

As of June 30, 2025, Imunon had approximately $4.7 million in cash and cash equivalents. During July 2025 the company received $3.1 million in net proceeds from the exercise of warrants and sales under the ATM facility. We estimate the company has sufficient capital to fund operations into the fourth quarter of 2025, however substantial additional capital will be necessary to complete the OVATION 3 trial. Following a 1-for-15 reverse split enacted on July 23, 2025, as of August 1, 2025 Imunon has approximately 2.2 million common shares outstanding. The company also recently announced a stock dividend, whereby 0.15 shares of common stock will be granted per each share of common stock outstanding. This will result in the issuance of approximately 448,000 shares, which are payable to holders of record as of August 7, 2025. When factoring in stock options, warrants, and the stock dividend we estimate the company has a fully diluted share count of approximately 3.8 million.

Conclusion

We're excited to see that Imunon has gotten the first patient dosed in the OVATION 3 trial and we look forward to updates from the company as the trial advances, including its efforts to secure financing for the study. The stock dividend is a nice reward for shareholders and shows the company is committed to making sure its interests align with those of current shareholders. We have adjusted our model to account for the reverse split and the July 2025 financing, and our valuation now stands at $45 per share.

PROJECTED FINANCIALS

Imunon, Inc.	2024 A	Q1 A	Q2 A	Q3 E	Q4 E	2025 E	2026 E	2027 E
IMNN-001	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
IMNN-101	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Other Income	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Total Revenues	**$0.0**	**$0.0**	**$0.0**	**$0.0**	**$0.0**	**$0.0**	**$0.0**	**$0.0**
CoGS	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
R&D	$11.6	$2.2	$1.2	$3.4	$3.6	$10.4	$14.0	$15.0
SG&A	$7.5	$2.0	$1.5	$2.0	$2.1	$7.6	$8.0	$9.0
Operating Income	($19.1)	($4.1)	($2.8)	($5.4)	($5.7)	($18.0)	($22.0)	($24.0)
Operating Margin	-	-	-	-	-	-	-	-
Interest & Other Income	$0.5	$0.0	$0.0	$0.1	$0.1	$0.3	$0.0	$0.0
Pre-Tax Income	($18.6)	($4.1)	($2.7)	($5.3)	($5.6)	($17.7)	($22.0)	($24.0)
Taxes & Other	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Tax Rate	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*
Net Income	($18.6)	($4.1)	($2.7)	($5.3)	($5.6)	($17.7)	($22.0)	($24.0)
Reported EPS	**($24.27)**	**($4.23)**	**($2.15)**	**($1.77)**	**($0.93)**	**($6.31)**	**($2.75)**	**($2.40)**
Weighted Shares Outstanding	0.8	1.0	1.3	3.0	6.0	2.8	8.0	10.0

Source: Zacks Investment Research, Inc. *David Bautz, PhD*

© Copyright 2025, Zacks Investment Research. All Rights Reserved.

HISTORICAL STOCK PRICE



Source: Zacks Small Cap Research

© Copyright 2025, Zacks Investment Research. All Rights Reserved.

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, David Bautz, PhD, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.